Adrian R. Krainer net worth and biography

Adrian Krainer Biography and Net Worth

Director of Stoke Therapeutics

Adrian Krainer, winner of the 2021 Wolf Prize in Medicine, the 2019 Breakthrough Prize in Life Sciences, the 2019 International Prize in Translational Neuroscience, and the 2019 RNA Society Lifetime Achievement Award, is a co-founder and director of Stoke Therapeutics. He is also the St. Giles Foundation Professor at Cold Spring Harbor Laboratory Cancer Center. Adrian’s fundamental and applied research on RNA splicing for over three decades directly led to the invention and development of Spinraza™ (nusinersen), the first approved therapeutic that corrects a splicing defect and a life-saving drug for infants with spinal muscular atrophy. He is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the National Academy of Inventors. Adrian was awarded the 2019 Breakthrough Prize for his work developing Spinraza, which the prize committee described as “one of the first of a promising new breed of antisense therapies.”

What is Adrian R. Krainer's net worth?: The estimated net worth of Adrian R. Krainer is at least $9.46 million as of March 10th, 2026. Krainer owns 283,302 shares of Stoke Therapeutics stock worth more than $9,462,287 as of March 23rd. This net worth estimate does not reflect any other assets that Krainer may own. Additionally, Krainer receives an annual salary of $44,000.00 as Director at Stoke Therapeutics. Learn More about Adrian R. Krainer's net worth.
How old is Adrian R. Krainer?: Krainer is currently 65 years old. There are 1 older executives and 6 younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics is Dr. Edward M. Kaye M.D., Ph.D., CEO & Director, who is 75 years old. Learn More on Adrian R. Krainer's age.
What is Adrian R. Krainer's salary?: As the Director of Stoke Therapeutics, Inc., Krainer earns $44,000.00 per year. There are 3 executives that earn more than Krainer. The highest earning executive at Stoke Therapeutics is Dr. Edward M. Kaye M.D., Ph.D., CEO & Director, who commands a salary of $948,900.00 per year. Learn More on Adrian R. Krainer's salary.
How do I contact Adrian R. Krainer?: The corporate mailing address for Krainer and other Stoke Therapeutics executives is 45 WIGGINS AVENUE, BEDFORD MA, 01730. Stoke Therapeutics can also be reached via phone at (781) 430-8200 and via email at [email protected]. Learn More on Adrian R. Krainer's contact information.
Has Adrian R. Krainer been buying or selling shares of Stoke Therapeutics?: During the past quarter, Adrian R. Krainer has sold $1,321,076.82 in shares of Stoke Therapeutics stock. Most recently, Adrian R. Krainer sold 33,243 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $39.74, for a transaction totalling $1,321,076.82. Following the completion of the sale, the director now directly owns 283,302 shares of the company's stock, valued at $11,258,421.48. Learn More on Adrian R. Krainer's trading history.
Who are Stoke Therapeutics' active insiders?: Stoke Therapeutics' insider roster includes Jonathan Allan (General Counsel), Jason Hoitt (Chief Patient Officer), Edward Kaye (), Edward Kaye (Director), Adrian Krainer (Director), Thomas Leggett (Chief Financial Officer), Arthur Levin (Director), Huw Nash (COO), Barry Ticho (Insider), and Arthur Tzianabos (Insider). Learn More on Stoke Therapeutics' active insiders.
Are insiders buying or selling shares of Stoke Therapeutics?: In the last twelve months, insiders at the sold shares 42 times. They sold a total of 367,800 shares worth more than $9,809,384.63. The most recent insider tranaction occured on March, 19th when insider Barry Ticho sold 1,461 shares worth more than $43,815.39. Insiders at Stoke Therapeutics own 9.5% of the company. Learn More about insider trades at Stoke Therapeutics.
Information on this page was last updated on 3/19/2026.

Adrian R. Krainer Insider Trading History at Stoke Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/10/2026	Sell	33,243	$39.74	$1,321,076.82	283,302
11/14/2025	Sell	40,472	$26.98	$1,091,934.56	364,246

Adrian R. Krainer Buying and Selling Activity at Stoke Therapeutics

Stoke Therapeutics Company Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $33.40

$33.37

$35.29

50 Day Range

MA: $32.61

$28.70

$38.35

2 Week Range

Now: $33.40

$5.35

$40.22

Volume

387,700 shs

Average Volume

770,783 shs

Market Capitalization

$1.98 billion

P/E Ratio

49.85

Dividend Yield

N/A

Beta

1.07

Adrian Krainer Biography and Net Worth

What is Adrian R. Krainer's net worth?

How old is Adrian R. Krainer?

What is Adrian R. Krainer's salary?

How do I contact Adrian R. Krainer?

Has Adrian R. Krainer been buying or selling shares of Stoke Therapeutics?

Who are Stoke Therapeutics' active insiders?

Are insiders buying or selling shares of Stoke Therapeutics?